Linvoseltamab-Gcpt 5 mg/2.5 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5 mg/2.5 mL
Reference Brands: Lynozyfic (USA/EU)
Category: Oncology Cancer Care
Linvoseltamab‑gcpt is a bispecific T‑cell engager antibody that binds to CD3 on T‑cells and BCMA on malignant plasma (myeloma) cells. This facilitates T‑cell activation and directs T cells to kill multiple myeloma cells. Lynozyfic is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, im‑modulatory agent and an anti‑CD38 antibody).
Linvoseltamab-Gcpt — third party manufacturing & bulk supply
Linvoseltamab-Gcpt 5 mg/2.5 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Linvoseltamab-Gcpt listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Linvoseltamab-Gcpt →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Linvoseltamab‑gcpt is used to treat adults with relapsed or refractory multiple myeloma, particularly those who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.
It is a bispecific T‑cell engaging antibody produced in cell culture, designed to bind CD3 on T‑cells and B‑cell maturation antigen (BCMA) on multiple myeloma cells, directing T‑cells to kill the cancer cells.
The trade name is Lynozyfic.
It is manufactured by Regeneron Pharmaceuticals, Inc.
The generic name is linvoseltamab‑gcpt.
The brand name is Lynozyfic.
It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cell culture and formulated as a sterile intravenous drug.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
